Interobserver Reproducibility of PD-L1 Biomarker in Non-small Cell Lung Cancer: A Multi-Institutional Study by 27 Pathologists
Background Assessment of programmed cell death-ligand 1 (PD-L1) immunohistochemical staining is used for treatment decisions in non-small cell lung cancer (NSCLC) regarding use of PD-L1/programmed cell death protein 1 (PD-1) immunotherapy. The reliability of the PD-L1 22C3 pharmDx assay is critical in guiding clinical practice. The Cardiopulmonary Pathology Study Group of the Korean Society of Pathologists investigated the interobserver reproducibility of PD-L1 staining with 22C3 pharmDx in NSCLC samples. Methods Twenty-seven pathologists individually assessed the tumor proportion score (TPS) for 107 NSCLC samples. Each case was divided into three levels based on TPS: <1%, 1%–49%, and ≥50%. Results The intraclass correlation coefficient for TPS was 0.902±0.058. Weighted κ coefficient for 3-step assessment was 0.748±0.093. The κ coefficients for 1% and 50% cut-offs were 0.633 and 0.834, respectively. There was a significant association between interobserver reproducibility and experience (formal PD-L1 training, more experience for PD-L1 assessment, and longer practice duration on surgical pathology), histologic subtype, and specimen type. Conclusions Our results indicate that PD-L1 immunohistochemical staining provides a reproducible basis for decisions on anti–PD-1 therapy in NSCLC..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:53 |
|---|---|
| Enthalten in: |
Journal of Pathology and Translational Medicine - 53(2019), 6, Seite 347-353 |
| Sprache: |
Englisch ; Koreanisch |
|---|
| Beteiligte Personen: |
Sunhee Chang [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Immunohistochemistry |
|---|
| doi: |
10.4132/jptm.2019.09.29 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ002219786 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ002219786 | ||
| 003 | DE-627 | ||
| 005 | 20230307022019.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4132/jptm.2019.09.29 |2 doi | |
| 035 | |a (DE-627)DOAJ002219786 | ||
| 035 | |a (DE-599)DOAJbc3a3416551a476fb5bac613c5da5be9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng |a kor | ||
| 050 | 0 | |a RB1-214 | |
| 100 | 0 | |a Sunhee Chang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Interobserver Reproducibility of PD-L1 Biomarker in Non-small Cell Lung Cancer: A Multi-Institutional Study by 27 Pathologists |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Background Assessment of programmed cell death-ligand 1 (PD-L1) immunohistochemical staining is used for treatment decisions in non-small cell lung cancer (NSCLC) regarding use of PD-L1/programmed cell death protein 1 (PD-1) immunotherapy. The reliability of the PD-L1 22C3 pharmDx assay is critical in guiding clinical practice. The Cardiopulmonary Pathology Study Group of the Korean Society of Pathologists investigated the interobserver reproducibility of PD-L1 staining with 22C3 pharmDx in NSCLC samples. Methods Twenty-seven pathologists individually assessed the tumor proportion score (TPS) for 107 NSCLC samples. Each case was divided into three levels based on TPS: <1%, 1%–49%, and ≥50%. Results The intraclass correlation coefficient for TPS was 0.902±0.058. Weighted κ coefficient for 3-step assessment was 0.748±0.093. The κ coefficients for 1% and 50% cut-offs were 0.633 and 0.834, respectively. There was a significant association between interobserver reproducibility and experience (formal PD-L1 training, more experience for PD-L1 assessment, and longer practice duration on surgical pathology), histologic subtype, and specimen type. Conclusions Our results indicate that PD-L1 immunohistochemical staining provides a reproducible basis for decisions on anti–PD-1 therapy in NSCLC. | ||
| 650 | 4 | |a programmed cell death-ligand 1 | |
| 650 | 4 | |a reproducibility | |
| 650 | 4 | |a observer variation | |
| 650 | 4 | |a immunohistochemistry | |
| 653 | 0 | |a Pathology | |
| 700 | 0 | |a Hyung Kyu Park |e verfasserin |4 aut | |
| 700 | 0 | |a Yoon-La Choi |e verfasserin |4 aut | |
| 700 | 0 | |a Se Jin Jang |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Journal of Pathology and Translational Medicine |d Korean Society of Pathologists & the Korean Society for Cytopathology, 2017 |g 53(2019), 6, Seite 347-353 |w (DE-627)DOAJ000047392 |x 23837845 |7 nnns |
| 773 | 1 | 8 | |g volume:53 |g year:2019 |g number:6 |g pages:347-353 |
| 856 | 4 | 0 | |u https://doi.org/10.4132/jptm.2019.09.29 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/bc3a3416551a476fb5bac613c5da5be9 |z kostenfrei |
| 856 | 4 | 0 | |u http://www.jpatholtm.org/upload/pdf/jptm-2019-09-29.pdf |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2383-7837 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2383-7845 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 53 |j 2019 |e 6 |h 347-353 | ||